The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity
Abstract
Programmed cell death 4 (Pdcd4), originally identified as an inhibitor of murine cellular transformation, inhibits protein synthesis by directly interacting with eukaryotic initiation factor 4A (eIF4A) of the translation initiation complex. The relevance of Pdcd4 to a broad range of human cancers derived from multiple tissue sites is unknown. Protein expression patterns from the National Cancer Institute drug-screening panel of 60 human cancer cells (NCI60) were analyzed by Western blot methods and revealed frequent reduction of Pdcd4 protein levels in renal-, lung-, and glia-derived tumors. Greater than mean Pdcd4 protein levels correlated with the antitumor activity of geldanamycin and tamoxifen. Stable expression of antisense PDCD4 significantly reduced the sensitivity of MCF-7 breast cancer cells to geldanamycin and to tamoxifen. Sensitivity to geldanamycin significantly increased in UO-31 renal cancer cells expressing sense PDCD4 cDNA. Increased geldanamycin sensitivity was accompanied by enhanced cell cycle arrest and apoptosis. One primary mode of inactivation of Pdcd4 in human cancers appears to involve down-regulated expression, and this down-regulation causes a decreased sensitivity to geldanamycin cytotoxicity. Thus, up-regulating Pdcd4 expression may be promising for geldanamycin-based combination therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been reported that PDCD4 upregulation sensitizes tumor cells to anti-tumor drugs such as cisplatin [104], gemcitabine [102], geldanamycin and tamoxifen [105].”
From Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions (2019) · cites this paper as [105]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Monks, A. P., Scudiero, D. A., Skehan, P., Shoemaker, R. H., Paull, K. D., Vistica, D. T., Hose, C. D., Langley, J. W., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,305
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
The multistep nature of cancer
Vogelstein, B., & Kinzler, K. W. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90209-z · Cited by 1,858
Weinberg, R. A. (1991) · Science · doi:10.1126/science.1659741 · Cited by 1,765
Regulation of matrix metalloproteinase expression in tumor invasion
Westermarck, J. K., & Kähäri, V. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.8.781 · Cited by 1,494
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M. C., Smith, L. H., Lee, J. K., Tanabe, L. K., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A. P., Scudiero, D. A., Rubinstein, L., Plowman, J., & Boyd, M. R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1088 · Cited by 970
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 778
Research works printed but not linked: 1
- Matsuhashi S, Yoshinaga H, Yatsuki H, Tsugita A, Hori K. Isolation of a novel gene from a human cell line with Pr-28 MAb which recognizes a nuclear antigen involved in the cell cycle. Res Commun Biochem Cell Mol Biol, 1997;1:109–20.
Cited by
Sorted by citations
Items 101–132 of 132
Programmed cell death 4 inhibits leptin-induced breast cancer cell invasion
Tari, A. (2011) · Oncology Reports · doi:10.3892/or.2011.1600 · Cited by 11
Diaryl Disulfides as Novel Stabilizers of Tumor Suppressor Pdcd4
Schmid, T., Blees, J. S., Bajer, M. M., Wild, J., Pescatori, L., Cuzzucoli Crucitti, G., Scipione, L., Costi, R., Henrich, C. J., Brüne, B., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151643 · Cited by 10
Self-citationThe Impact of Pdcd4, a Translation Inhibitor, on Drug Resistance
Wang, Q., & Yang, H. (2024) · Pharmaceuticals · doi:10.3390/ph17101396 · Cited by 10
Yu, H., Wan, L., Tang, Z., Yao, C., Zhang, D., Jiang, M., Wang, C., Liu, Y., Xue, C., Wang, X., et al. (2022) · Oncology Reports · doi:10.3892/or.2022.8331 · Cited by 10
PDCD4 interacting with PIK3CB and CTSZ promotes the apoptosis of multiple myeloma cells
Liu, L., Feng, X., Fan, C., Kong, D., Feng, X., Sun, C., Xu, Y., Li, B., Jiang, Y. Z., & Zheng, C. (2024) · The FASEB Journal · doi:10.1096/fj.202400687r · Cited by 10
Eto, K., Eda, K., Hayano, M., Goto, S., Nagao, K., Kawasaki, T., Kashimura, H., Tarui, H., Nishimura, O., Agata, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.018622 · Cited by 9
Ferris, W. F., Marriott, C., Ali, T., Landy, C., Campbell, S. C., & Macfarlane, W. M. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181f5f1ab · Cited by 8
Holčík, M., Lewis, S. M., Pardo, O. E., Seckl, M. J., Liwak, U., Thakor, N., Jordan, L. E., & Roy, R. (2012) · Cited by 7
Wang, D., Guo, S., Han, S., Xu, N., Guo, J., & Sun, Q. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1841 · Cited by 6
MicroRNA-Assisted Hormone Cell Signaling in Colorectal Cancer Resistance
Massaro, C., Safadeh, E., Sgueglia, G., Stunnenberg, H. G., Altucci, L., & Dell’Aversana, C. (2020) · Cells · doi:10.3390/cells10010039 · Cited by 6
Huang, H., Ru, S.-J., Chen, J., Liu, W., Fang, S., Liu, Q., Meng, Q., Liu, P., & Zhou, H. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s500439 · Cited by 5
Wang, Y., Ding, L., Zhang, X., Zhao, M., Qu, Z., Huang, S., Zhang, Y., Li, Y., & Gao, F. (2012) · Medical Oncology · doi:10.1007/s12032-012-0185-0 · Cited by 5
Wang, Y., Cui, L., Wu, W., Quinn, M. J., Menon, R., Zhao, J., & Zhang, H.-J. (2022) · Placenta · doi:10.1016/j.placenta.2022.10.014 · Cited by 5
Jiang, Y. Z., Zhang, S.-H., Han, G.-Q., & Qin, C.-Y. (2009) · Journal of International Medical Research · doi:10.1177/147323000903700424 · Cited by 3
Pdcd4 targets eIF4A to inhibit translation, transcription, tumorigenesis, and invasion
Colburn, N. H., Yang, H., & Jansen, A. P. (2006) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2006.04.053 · Cited by 3
Self-citationYang, H., Wang, Q., Bajer, M. M., & Schmid, T. (2014) · Springer eBooks · doi:10.1007/978-94-017-9078-9_6 · Cited by 3
Yan, Y., Wang, W., Liu, Z., Lv, X., Li, M., Yang, W., Wang, L., & Song, L. (2020) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2020.02.038 · Cited by 2
Lee, A., Kim, N., & Park, S. W. (2004) · Pigment Cell Research · doi:10.1111/j.1600-0749.2004.00186.x · Cited by 2
Jiamin, D., 陈作良, Chen, W., Ma, Z., Xie, Y., & Xie, Y. (2021) · Research Square · doi:10.19852/j.cnki.jtcm.2022.05.003 · Cited by 1
Translational control : mTOR signalling and the use of next-generation sequencing methods
Jackson, T. J. (2013) · Nottingham ePrints (University of Nottingham)
Pharmacogenetic studies in multiple myeloma
Corthals, S. L. (2011) · RePub (Erasmus University Rotterdam)
Jordan, L. E. (2011) · uO Research (University of Ottawa) · doi:10.20381/ruor-4562
Tomenson, M. (2010) · TSpace (University of Toronto)
Parsyan, A. E., Seront, E., & Machiels, J. (2014) · Springer eBooks · doi:10.1007/978-94-017-9078-9_34
Parsyan, A. E., Gonzalez-Angulo, A. M., Zardavas, D., Piccart, M. J., & Meterissian, S. H. (2014) · Springer eBooks · doi:10.1007/978-94-017-9078-9_26
Data from Silibinin inhibits translation initiation: implications for anticancer therapy
Lin, C., Sukarieh, R., & Pelletier, J. (2023) · doi:10.1158/1535-7163.c.6531872
Data from Silibinin inhibits translation initiation: implications for anticancer therapy
Lin, C., Sukarieh, R., & Pelletier, J. (2023) · doi:10.1158/1535-7163.c.6531872.v1
Allen, N. (2023) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/4094
Silva, J. S., Costa, M., & Pereira, F. (2022) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/wg1ki8fsew
Jin, Y., Desai, V., Mazzaroth, J., & Wickstrom, E. (2025) · NAR Cancer · doi:10.1093/narcan/zcaf053
BindingDB (2013) · UC San Diego · doi:10.7270/q23r0v1x
Metadata
- Authors
- Jansen, A. P., Camalier, C. E., Stark, C., & Colburn, N. H.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- Venue
- Molecular Cancer Therapeutics
- Published
- 2004-02-01
- Volume
- 3
- Issue
- 2
- Pages
- 103-110
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2257484201
- Cited by
- 132
- References
- 46
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 4 · 2019: 4 · 2018: 2 · 2017: 4 · 2016: 4 · 2015: 6 · 2014: 9 · 2013: 6 · 2012: 9
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- PDCD4, eIF4A, translation initiation, drug sensitivity, geldanamycin, tamoxifen, kidney cancer, breast cancer, apoptosis, cell cycle arrest, combination therapy, tumor suppressor
- MeSH terms
- Antineoplastic Agents, Cell Division, Drug Screening Assays, Antitumor, Humans, Kidney Neoplasms, Mitosis, Neoplasms, Prognosis, Quinones, RNA, Messenger, Tamoxifen, Retinoblastoma Protein, G2 Phase, Benzoquinones, Tacrolimus, RNA-Binding Proteins, Cell Line, Tumor, Lactams, Macrocyclic, Apoptosis Regulatory Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
